(4-Piperidinyl)-piperazine: A new platform for acetyl-CoA carboxylase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 23, 2009, Pages 6645-6648

  Chonan, Tomomichi ^a   Oi, Takahiro ^a   Yamamoto, Daisuke ^a   Yashiro, Miyoko ^a   Wakasugi, Daisuke ^a   Tanaka, Hiroaki ^a   Ohoka Sugita, Ayumi ^a   Io, Fusayo ^a   Koretsune, Hiroko ^a   Hiratate, Akira ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

(4 Piperidinyl) piperazine; Acetyl CoA carboxylase; Inhibitor

Indexed keywords

(4 PIPERIDINYL) PIPERAZINE; ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE INHIBITOR; ENZYME; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ACETYL-COA CARBOXYLASE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PIPERAZINES; PIPERIDINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; MUS MUSCULUS;

EID: 71749083654     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.012     Document Type: Article

References (11)

1. Harwood Jr. H.J., Petras S.F., Shelly L.D., Zaccaro L.M., Perry D.A., Makowski M.R., Hargrove D.M., Martin K.A., Tracey W.R., Chapman J.G., Magee W.P., Dalvie D.K., Soliman V.F., Martin W.H., Mularski C.J., and Eisenbeis S.A. J. Biol. Chem. 278 (2003) 37099
2. Harwood Jr. H.J. Exp. Opin. Cardiovasc. Renal. 9 (2005) 267
3. Corbett J.W., and Harwood Jr. H.J. Rec. Pat. Cardiovasc. Drug Discovery 2 (2007) 162
4. Abu-Elheiga L., Matzuk M.M., Abo-Hashema K.A., and Wakil S.J. Science 291 (2001) 2613
5. Metabolic stability in liver microsomes: 5 μM compound was incubated at 37 °C in 1 mg/mL human or rat microsomes supplemented with 1.5 mM glucose-6-phosphate, 0.16 mM β-nicotinamide-adenine dinucleotide phosphate, 1 U/mL glucose-6-phosphate dehydrogenase, 250 mM phosphate buffer, 2.4 mM magnesium chloride and 69 mM potassium chloride. Concentrations of the test compound were determined by LC-MS/MS. Metabolic stability was calculated from the ratio of the test compound concentration at 0 min to its concentration after15-min incubation.
6. Zhang H., Tweel B., Li J., and Tong L. Structure 12 (2004) 1683
7. Tong L. Cell. Mol. Life Sci. 62 (2005) 1784
8. MOE (Molecular Operating Environment); Chemical Computing Group: Montreal, Quebec, Canada, 2006.
9. Anne M., and William J.R. J. Clin. Invest. 79 (1987) 59
10. Shinde P., Srivastava S.K., Odedara R., Tuli D., Munshi S., Patel J., Zambad S.P., Sonawane R., Gupta R.C., Chauthaiwale V., and Dutt C. Bioorg. Med. Chem. Lett. 19 (2009) 949
11. Dong C., Ching-Hsuen C., Luping C., John N.F., Gabe A.M., Yuli W., Joseph W.C., Mark R.H., Gregory A.L., Yongmi A., and James K.T. Protein Exp. Purif. 51 (2007) 11